As a proof of concept and to validate our isolation technology, we use immune recognition to specifically isolate cells expressing two specific antigens—EpCAM [27] and EGFR [28]—which have been thoroughly studied as biomarkers for the targeting of breast cancer cells [29,30]. The gene discussed is EPCAM; the disease is breast carcinoma.